Opinion

Video

ASH 2023 Updates on Frontline Therapies in MCL

Author(s):

Grzegorz S. Nowakowski, MD,Jennifer Crombie, MD

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Related Videos
Elizabeth Buchbinder, MD
Grzegorz S. Nowakowski, MD, and Samuel Yamshon, MD, break down the current treatment landscape for relapsed/refractory follicular lymphoma.
Ashkan Emadi, MD, PhD
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Eunice S. Wang, MD
Related Content
Acute Myeloid Leukemia | stock.adobe.com
December 20th 2024

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital
November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

CP-CML | Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com
December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

Mantle cell lymphoma | Image Credit: © Tatiana Shepeleva – stock.adobe.com
December 18th 2024

Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL